Undisclosed VRK1 inhibitor
/ Sprint Bioscience
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2026
Selective VRK1 inhibition reduces glioblastoma growth via synthetic lethality in vitro and in vivo
(EORTC-NCI-AACR 2026)
- "Abstract will be available as of 4 November (with consent of the author)"
Preclinical • Synthetic lethality • Brain Cancer • Glioblastoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1